hVIVO plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPORF research report →
Companywww.hvivo.com
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations.
- CEO
- Yamin Mohammed Khan
- IPO
- 2020
- Employees
- 301
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $59.27M
- P/E
- -9.13
- P/S
- 1.15
- P/B
- 1.43
- EV/EBITDA
- -262.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -6.07%
- Op Margin
- -13.13%
- Net Margin
- -12.48%
- ROE
- -14.65%
- ROIC
- -11.14%
Growth & Income
- Revenue
- $46.77M · -25.44%
- Net Income
- $-5,992,028.4 · -156.25%
- EPS
- $-0.01 · -155.41%
- Op Income
- $-348,942
- FCF YoY
- -287.88%
Performance & Tape
- 52W High
- $0.35
- 52W Low
- $0.09
- 50D MA
- $0.09
- 200D MA
- $0.16
- Beta
- 1.69
- Avg Volume
- 468
Get TickerSpark's AI analysis on OPORF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our OPORF Coverage
We haven't published any research on OPORF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OPORF Report →